These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 1376208)

  • 21. Prostatic origin of metastases: immunoperoxidase localization of prostate-specific antigen.
    Ghazizadeh M; Kagawa S; Maebayashi K; Izumi K; Kurokawa K
    Urol Int; 1984; 39(1):9-12. PubMed ID: 6203202
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circulating prostate-specific antigen/CD14-double-positive cells: a biomarker indicating low risk for hematogeneous metastasis of prostate cancer.
    Brandt B; Griwatz C; Brinkmann O; Zänker KS
    J Natl Cancer Inst; 1997 Jan; 89(2):174. PubMed ID: 8998191
    [No Abstract]   [Full Text] [Related]  

  • 23. Clinical usefulness of prostate-specific antigen and prostatic acid phosphatase in patients with prostatic cancer.
    Filella X; Molina R; Jo J; Umbert B; Bedini JL; Ballesta AM
    Tumour Biol; 1990; 11(6):289-94. PubMed ID: 1700860
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of metallopanstimulin and oncogenesis in human prostatic carcinoma.
    Fernandez-Pol JA; Fletcher JW; Hamilton PD; Klos DJ
    Anticancer Res; 1997; 17(3A):1519-30. PubMed ID: 9179190
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognosis: Proportionate response.
    DeWeerdt S
    Nature; 2015 Dec; 528(7582):S124-5. PubMed ID: 26672783
    [No Abstract]   [Full Text] [Related]  

  • 26. The identification of prostate-specific antigen.
    Ablin RJ
    J Clin Lab Anal; 1991; 5(1):78. PubMed ID: 1705582
    [No Abstract]   [Full Text] [Related]  

  • 27. [Prostatic-specific antigen. A new tumor marker].
    Morote Robles J; Ruibal Morell A
    Med Clin (Barc); 1985 Dec; 85(19):801-4. PubMed ID: 2419714
    [No Abstract]   [Full Text] [Related]  

  • 28. [The role of PSA in diagnosis of prostate cancer and its recurrence].
    Vergho DC; Heine K; Wolff JM
    Pathologe; 2005 Nov; 26(6):473-8. PubMed ID: 16215709
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Diagnostic and prognostic value of serum phosphatases and PSA (prostate-specific antigen) in prostatic carcinoma].
    Sohn M; Studer UE
    Schweiz Rundsch Med Prax; 1988 May; 77(20):551-5. PubMed ID: 2455317
    [No Abstract]   [Full Text] [Related]  

  • 30. [PSA recurrence after primary curative therapy--local or systemic? When is a second curative therapy still possible?].
    Wirth MP; Engelhardt FM
    Urologe A; 2005 Sep; 44(9):997-1004, 1006-7. PubMed ID: 16133232
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer.
    Ritter MA; Messing EM; Shanahan TG; Potts S; Chappell RJ; Kinsella TJ
    J Clin Oncol; 1992 Aug; 10(8):1208-17. PubMed ID: 1378886
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted PET imaging for prostate-specific membrane antigen in prostate cancer.
    Hope TA; Aggarwal RR; Westphalen AC; Cooperberg MR; Greene KL
    Future Oncol; 2016 Nov; 12(21):2393-2396. PubMed ID: 27453303
    [No Abstract]   [Full Text] [Related]  

  • 33. Correlation of serum β2-microglobulin levels with prostate-specific antigen, Gleason score, clinical stage, tumor metastasis and therapy efficacy in prostate cancer.
    Zhang YX; Wang L; Ji PY; Zhao GG; Zhong GP; Wang ZP
    Arch Med Res; 2013 May; 44(4):259-65. PubMed ID: 23707648
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostate-specific membrane antigen: current and future utility.
    Gregorakis AK; Holmes EH; Murphy GP
    Semin Urol Oncol; 1998 Feb; 16(1):2-12. PubMed ID: 9508077
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes in prostate-specific markers under chronic gonadotrophin-releasing hormone analogue treatment of state D prostatic cancer.
    Matzkin H; Lewyshon O; Ayalon D; Braf Z
    Cancer; 1989 Apr; 63(7):1287-91. PubMed ID: 2465816
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Present and future management of prostate cancer.
    de Vere White R
    Cancer Biother Radiopharm; 2000 Apr; 15(2):121-5. PubMed ID: 10803316
    [No Abstract]   [Full Text] [Related]  

  • 37. [Prostate cancer screening with a new marker based on circulating blood macrophages?].
    Herwig R; Djavan B; Kramer G; El-Taieb MA; Kühhas F; Leers M; Marberger M
    Urologe A; 2007 Sep; 46(9):1066-70. PubMed ID: 17622505
    [No Abstract]   [Full Text] [Related]  

  • 38. The time is ripe to redefine high-risk prostate cancer?
    Lim SK; Rha KH
    BJU Int; 2014 Feb; 113(2):181. PubMed ID: 24712698
    [No Abstract]   [Full Text] [Related]  

  • 39. [Role of the markers PAP-PSA in the diagnosis of cancer of the prostate].
    Petrone U; Gaspari G; Marascia G; Magnocavallo N; Petrone D; Tucci C
    Minerva Urol Nefrol; 1990; 42(2):73-5. PubMed ID: 1697431
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Editorial comment.
    Epstein JI
    Urology; 2013 Jul; 82(1):152-3; discussion 153. PubMed ID: 23706589
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.